$0.230000
0.00813.65%
Last update: 9:16 AM
15 minutes delayed
Comments
Loading...
Kintara Therapeutics
KTRANASDAQ
Kintara Therapeutics (NASDAQ:KTRA) Stock, Analyst Ratings, Price Targets, Forecasts
Kintara Therapeutics Inc has a consensus price target of $7.33 based on the ratings of 4 analysts. The high is $14 issued by Maxim Group on July 14, 2023. The low is $3 issued by HC Wainwright & Co. on January 20, 2022. The 3 most-recent analyst ratings were released by Maxim Group, HC Wainwright & Co., and Aegis Capital on July 14, 2023, January 20, 2022, and September 30, 2021, respectively. With an average price target of $7.33 between Maxim Group, HC Wainwright & Co., and Aegis Capital, there's an implied 3088.41% upside for Kintara Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Maxim Group
HC Wainwright & Co.
Aegis Capital
1calculated from analyst ratings
Analyst Ratings for Kintara Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/14/2023 | Buy Now | 5986.96% | Maxim Group | Jason McCarthy | → $14 | Upgrade | Hold → Buy | Get Alert |
| 09/29/2022 | Buy Now | — | Maxim Group | Jason McCarthy | — | Downgrade | Buy → Hold | Get Alert |
| 05/16/2022 | Buy Now | — | Dawson James | Jason Kolbert | — | Downgrade | Buy → Neutral | Get Alert |
| 01/20/2022 | Buy Now | 1204.35% | HC Wainwright & Co. | Michael King | $300 → $150 | Maintains | Buy | Get Alert |
| 09/30/2021 | Buy Now | 2073.91% | Aegis Capital | Nathan Weinstein | — | Maintains | Buy | Get Alert |
| 09/28/2021 | Buy Now | 2508.7% | HC Wainwright & Co. | Michael King | — | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Kintara Therapeutics (KTRA) stock?
The latest price target for Kintara Therapeutics (NASDAQ:KTRA) was reported by Maxim Group on July 14, 2023. The analyst firm set a price target for $14.00 expecting KTRA to rise to within 12 months (a possible 5986.96% upside). 0 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Kintara Therapeutics (KTRA)?
The latest analyst rating for Kintara Therapeutics (NASDAQ:KTRA) was provided by Maxim Group, and Kintara Therapeutics upgraded their buy rating.
When was the last upgrade for Kintara Therapeutics (KTRA)?
The last upgrade for Kintara Therapeutics Inc happened on July 14, 2023 when Maxim Group raised their price target to $14. Maxim Group previously had a hold for Kintara Therapeutics Inc.
When was the last downgrade for Kintara Therapeutics (KTRA)?
The last downgrade for Kintara Therapeutics Inc happened on September 29, 2022 when Maxim Group changed their price target from N/A to N/A for Kintara Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Kintara Therapeutics (KTRA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kintara Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kintara Therapeutics was filed on July 14, 2023 so you should expect the next rating to be made available sometime around July 14, 2024.
Is the Analyst Rating Kintara Therapeutics (KTRA) correct?
While ratings are subjective and will change, the latest Kintara Therapeutics (KTRA) rating was a upgraded with a price target of $0.00 to $14.00. The current price Kintara Therapeutics (KTRA) is trading at is $0.23, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.